Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2025
0mins
Source: Benzinga
First Human Death from H5 Bird Flu: The U.S. reported its first human death from the H5 bird flu strain, leading to increased stock prices for vaccine developers like Moderna and Pfizer, while health officials monitor the outbreak with 66 confirmed cases in the country.
Vaccine Development and Investment Opportunities: Traditional vaccines are already stockpiled, and companies like Moderna are developing updated mRNA vaccines; investors can consider ETFs that include biotech firms involved in vaccine production as a way to capitalize on the ongoing situation.
Analyst Views on IDNA
Wall Street analysts forecast IDNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDNA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 29.500
Low
Averages
High
Current: 29.500
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
